CT colonography screening in extracolonic cancer survivors: impact on rates of colorectal and extracolonic findings by cancer type
To compare the rates of colorectal and extracolonic findings at CT colonography (CTC) screening between patients with and without a personal prior history of other.
Over a 160-month interval, 349 adults (mean age, 60.3 years; 67% female) with a positive history of extracolonic cancer [Ca(+)], excluding 271 patients with isolated non-melanoma skin cancers, underwent CTC screening. This study cohort was compared against 8859 controls (mean age, 57.0 years; 53% female) without a prior cancer history [Ca(−)]. Primary outcome measures included the rates of relevant colorectal (C-RADS C2–C4) and extracolonic (C-RADS E3-E4) findings at CTC. Wilcoxon rank sum test was used to test for statistical significance with post-hoc analysis by relative rate (RR).
Both colorectal (C2–C4) and extracolonic (E3–E4) findings were significantly increased in the Ca(+) group versus Ca(−) control group (p = 0.0283 and 0.0236, respectively). Positive colorectal findings were most notably increased among survivors of non-small cell lung cancer (RR 3.1), head/neck cancers (RR, 3.4), and bladder cancers (RR 2.2). The proportion of C2–C4 patients undergoing intervention in the Ca(+) cohort was not significantly different than the Ca(−). Potentially relevant extracolonic findings (E3) were increased in survivors of hematogenous malignancies (RR 2.0), while likely important extracolonic findings (E4) were increased in survivors of female gynecological malignancies (RR 3.4).
Relevant colorectal and extracolonic findings at CTC screening are increased in patients with a previous extracolonic cancer history, particularly among certain cancer subsets. These results may have important implications for choice of colorectal test in these patients.
KeywordsCT colonography Cancer history Colorectal cancer Cancer screening
MEL was supported by Ruth L Kirschstein National Research Service Award F30CA189673 from the National Cancer Institute, and by T32GM008692 from the National Institute of General Medical Sciences awarded to the University of Wisconsin-Madison Medical Scientist Training Program.
Compliance with ethical standards
Disclosure of potential conflicts of interest
Dr. Pickhardt is co-founder of VirtuoCTC; shareholder in Elucent, SHINE, Cellectar Biosciences; and advisor to Bracco.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
For this type of study, formal consent is not required.
- 1.Noone A, Howler N, M K, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (2018) SEER Cancer Statistics Review 1975–2015, National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/.
- 3.Curtis R, Freedman D, Ron E, Ries L, Hacker D, Edwards B, Tucker M, Faumeni J (2006) New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, vol NIH Publ. No. 05-5302. National Cancer Institute, Bethesda, MDGoogle Scholar
- 13.Pickhardt PJ, Choi JR, Nugent PA, Schindler WR (2004) The effect of diagnostic confidence on the probability of optical colonoscopic confirmation of potential polyps detected on CT colonography: prospective assessment in 1339 asymptomatic adults. Am J Roentgenol 183(6):1661–1665CrossRefGoogle Scholar
- 16.Brown L, McCarron P, Freedman D (2006) New Malignancies Following Cancer of the Buccal Cavity and Pharynx. In: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, vol Publ. No. 05-5302. National Cancer Institute, Bethesda, MDGoogle Scholar
- 17.Caporaso N, Dodd K, Tucker M (2006) New Malignancies Following Cancer of the Respiratory Tract. In: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, vol NIH Publ. No. 05-5302. National Cancer Institute, Bethesda, MDGoogle Scholar
- 19.Wilson R, Silverman D, Fraument J, Curtis R (2006) New Malignancies Following Cancer of the Urinary Tract. In: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, vol NIH Publ. No. 05-5302. Cancer Institute, Bethesda, MDGoogle Scholar
- 20.Dores G, Coté T, Travis L (2006) New Malignancies Following Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma. In: New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, vol NIH Publ. No. 05-5302. National Cancer Institute, Bethesda, MDGoogle Scholar